万拉法新与西酞普兰治疗抑郁症对照研究

A control study on venlafaxine vs.citaloparm in the treatment of depression

目的评价万拉法新与西酞普兰治疗抑郁症的临床疗效及安全性。方法将65例抑郁症患者随机分为万拉法新组32例,西酞普兰组33例,观察6w。于治疗前和治疗1w、2w、6w末采用汉密顿抑郁量表评定疗效,副反应量表评定不良反应。结果万拉法新组显效率80.6%,西酞普兰组77.4%,两组比较差异无显著性(P>0.05);治疗第1w末万拉法新组汉密顿抑郁量表评分显著低于西酞普兰组(P<0.05)。2w、4w、6w末两组评分比较差异无显著性(P>0.05);万拉法新组不良反应发生率46.9%,西酞普兰组39.4%,两组比较差异无显著性(P>0.05)。结论万拉法新与西酞普兰治疗抑郁症具有同等疗效,但万拉发新起效较西酞普兰快。

Objective To evaluate the clinical curative effects and safety of venlafaxine vs. citaloparm in the treatment of depression. Methods 65 patients with depressive disorder were randomly divided into venlafaxine（n= 32） and citaloparm （n= 33） group for 6 weeks. The curative effects were assessed with the Hamilton Depression Scale （HAMD） and adverse effects with the Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of the 1st, 2nd and 6th week, respectively. Results Excellence rates were respectively 80.6% in venlafaxine and 77.4G in the citaloparm group, which showed no significant difference（P〉0.05） ; at the end of the 1st week, score of the HAMD was significantly lower in the venlafaxine than in the citaloparm group（P〈0.05）. There were no significant differences at the ends of the 2nd, 4th and 6th week between the 2 groups（P〉0.05）; incidences of adverse effects were respectively 46. 9% in the venlafaxine and 39.4% in the citaloparm group, difference was not significant（P〉0.05）. Conclusion Venlafaxine has therapeutic equivalence to citaloparm in depression, but takes effects faster .